You are here: Industry Insights > GT Biopharma

News List

GT Biopharma Appoints Gregory Berk CMO contractpharma
April 27, 2021
Jeffrey S. Miller, M.D. will become Consulting Chief Scientific Officer, continuing to lead TriKE product candidate clinical trials.
Novel natural killer cell engager therapy shows promise in Phase I trials europeanpharmaceuticalreview
April 15, 2021
GTB-3550 TriKE™ monotherapy was found to restore natural killer cell function and immune surveillance in relapsed or refractory AML and MDS cancer patients.
GT Biopharma and Cytovance Biologics Expand Partnership contractpharma
October 12, 2020
Cytovance will be the exclusive GMP manufacture for three of the company's TriKE therapeutic product candidates.
GT Biopharma Provides GTB-1550 Clinical Development Update americanpharmaceuticalreview
May 31, 2019
GT Biopharma has provided an update with respect to the further clinical development of GTB-1550.
GT Biopharma Receives Institutional Review Board Approval to Proceed With in Human FDA Phase 1 Clinical Trial americanpharmaceuticalreview
April 11, 2019
GT Biopharma Receives Institutional Review Board Approval to Proceed With in Human FDA Phase 1 Clinical Trial.
GT Biopharma appoints David Cardino as VP, Finance biospectrumasia
August 28, 2018
David Cardino is a financial and operational leader with over 15 years of experience in the pharmaceutical and biotech industries
GT Biopharma, Inc. Announces Additional Positive Data From Its Phase 1 Clinical Trial For Myasthenia Gravis and Potential for Acceleration of the Start of Its Phase 2 Trial biospace
March 27, 2018
GT Biopharma Inc.today announced that it has completed the analysis of pharmacokinetic data from its Phase 1 clinical trial for GTP-004, its promising treatment for the symptoms of myasthenia gravis.